title: Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy.
abstract: OBJECTIVE
  Levetiracetam (LEV) is a new antiepileptic drug that has been found to be effective as an adjunctive therapy for uncontrolled partial seizures. However, the results of several studies suggested that LEV has negative psychotropic effects, including irritability, aggressiveness, suicidality, and mood disorders. We investigated the impact of adjunctive LEV on psychiatric symptoms and quality of life (QOL) in patients with drug-refractory epilepsy (DRE) and determined the risk factors provoking psychiatric adverse events.
  
  
  METHODS
  A 24-week, prospective, open-label study was conducted. At enrollment, we interviewed patients and reviewed their medical charts to collect demographic and clinical information. They were asked to complete self-report health questionnaires designed to measure various psychiatric symptoms and QOL at enrollment and 24 weeks later.
  
  
  RESULTS
  Seventy-one patients were included in the study, 12 patients (16.9%) of whom discontinued LEV therapy due to serious adverse events including suicidality. The risk factor for premature withdrawal was a previous history of psychiatric diseases (odds ratio 4.59; 95% confidence interval, 1.22-17.32). LEV intake resulted in significant improvements in Beck Anxiety Inventory score (p<0.01) and some domains of the Symptom Checklist-90-Revised, such as somatization (p<0.05), obsessive-compulsiveness (p<0.05), depression (p<0.05), and anxiety (p<0.05). These improvements were not related to the occurrence of seizure freedom. The Quality of Life in Epilepsy Inventory-31 overall score and subscale scores, such as seizure worry (p<0.01), overall QOL (p<0.05), emotional well-being (p<0.05), energy-fatigue (p<0.05), and social function (p<0.05), also improved.
  
  
  CONCLUSIONS
  Adjunctive LEV in patients with DRE is likely to improve psychiatric symptoms and QOL. Clinicians should be well aware of the psychiatric histories of patients to prevent them from developing serious adverse events related to LEV.
authors.affiliation: Department of Neurology, Daegu Fatima Hospital, Daegu, Korea.
authors.forename: Jang-Joon
authors.initials: JJ
authors.lastname: Lee
authors.forename: Hyun-Seok
authors.initials: HS
authors.lastname: Song
authors.forename: Yang-Ha
authors.initials: YH
authors.lastname: Hwang
authors.forename: Ho-Won
authors.initials: HW
authors.lastname: Lee
authors.forename: Chung-Kyu
authors.initials: CK
authors.lastname: Suh
authors.forename: Sung-Pa
authors.initials: SP
authors.lastname: Park
references.citation: Epilepsia. 2002 Jun;43(6):644-51
references.pmid: 12060025
references.citation: J Clin Neurol. 2010 Jun;6(2):81-8
references.pmid: 20607047
references.citation: Epilepsy Behav. 2010 Aug;18(4):455-9
references.pmid: 20591744
references.citation: Adv Neurol. 1991;55:127-42
references.pmid: 2003402
references.citation: Epilepsia. 2007 Dec;48(12):2322-6
references.pmid: 17711462
references.citation: Neurology. 2010 Jul 27;75(4):335-40
references.pmid: 20660863
references.citation: Epilepsy Behav. 2007 Mar;10(2):296-303
references.pmid: 17317325
references.citation: CNS Drugs. 2006;20(12):969-79
references.pmid: 17140277
references.citation: Epilepsia. 2009 Mar;50(3):434-42
references.pmid: 19016830
references.citation: CNS Drug Rev. 2007 Spring;13(1):57-78
references.pmid: 17461890
references.citation: Epilepsy Behav. 2007 Aug;11(1):130-2
references.pmid: 17544331
references.citation: Epilepsy Res. 2001 Nov;47(1-2):77-90
references.pmid: 11673023
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
references.pmid: 15210974
references.citation: Epilepsy Behav. 2007 Feb;10(1):105-10
references.pmid: 17079191
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):539-43
references.pmid: 18031881
references.citation: Epileptic Disord. 2003 May;5 Suppl 1:S57-63
references.pmid: 12915343
references.citation: Neurology. 1999;53(5 Suppl 2):S53-67
references.pmid: 10496235
references.citation: Epileptic Disord. 2009 Mar;11(1):1-9
references.pmid: 19258231
references.citation: Epilepsy Behav. 2009 Nov;16(3):468-74
references.pmid: 19783219
references.citation: Epilepsy Behav. 2010 Jul;18(3):291-8
references.pmid: 20547106
references.citation: Epilepsia. 2006;47 Suppl 2:28-33
references.pmid: 17105456
references.citation: Clin Neuropharmacol. 2005 Mar-Apr;28(2):72-8
references.pmid: 15795549
references.citation: Epilepsia. 1981 Aug;22(4):489-501
references.pmid: 6790275
references.citation: Epilepsia. 1997 Mar;38(3):353-62
references.pmid: 9070599
references.citation: Epilepsy Behav. 2003 Apr;4(2):124-32
references.pmid: 12697136
references.citation: Neurology. 2000 Jul 25;55(2):236-42
references.pmid: 10908898
references.citation: Neurology. 2001 Jun 12;56(11):1445-52
references.pmid: 11402099
references.citation: Epilepsia. 2001;42 Suppl 4:36-9
references.pmid: 11564124
references.citation: Epilepsy Behav. 2006 Nov;9(3):424-31
references.pmid: 16949344
references.citation: Epilepsy Behav. 2008 Oct;13(3):535-41
references.pmid: 18583196
references.citation: Seizure. 2007 Jul;16(5):402-9
references.pmid: 17369059
references.citation: Epilepsia. 2002 May;43(5):535-8
references.pmid: 12027916
references.citation: Epilepsy Behav. 2004 Jun;5(3):337-42
references.pmid: 15145303
references.citation: Epilepsy Behav. 2006 May;8(3):588-92
references.pmid: 16473557